Josh Gad says he's taking 'life-changing' GLP-1 medication for weight loss but admits that it can't replace having a healthy ...
For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...
(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...
In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).
According to Science Alert, treating mice with a metabolite produced by Bacteroides vulgatus resulted in improved blood sugar ...
An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the findings need clinical testing.
The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, when a causative role of the drug is implausible, suggested stepped-up ...
Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...
Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have ...
Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.